Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration
Gain Therapeutics presented positive 12-month open-label extension data from its Phase 1b study of rexaceract in Parkinson's disease patients. The data showed stabilization of motor scores (MDS-UPDRS Parts II and III) with no significant disease progression or safety concerns, supporting the drug’s disease-modifying potential. The company plans to …